Arglabin could target inflammasome-induced ARDS and cytokine storm associated with COVID-19

被引：0
作者：
Azadeh Manayi
Seyed Mohammad Nabavi
Maryam Khayatkashani
Solomon Habtemariam
Hamid Reza Khayat Kashani
机构：
[1] Tehran University of Medical Sciences,Faculty of Pharmacy, Medicinal Plants Research Center
[2] Baqiyatallah University of Medical Sciences,Applied Biotechnology Research Center
[3] Tehran University of Medical Sciences,School of Iranian Traditional Medicine
[4] University of Greenwich,Pharmacognosy Research Laboratories and Herbal Analysis Services
[5] Shahid Beheshti University of Medical Sciences,Imam Hossein Hospital
来源：
Molecular Biology Reports | 2021年 / 48卷
关键词：
Asteraceae; Arglabin; Corona virus; COVID-19; Anti-inflammation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Arglabin (l(R),10(S)-epoxy-5(S),5(S),7(S)-guaia-3(4),ll(13)-dien-6,12-olide), is a natural sesquiterpene γ-lactone which was first isolated from Artemisia glabella. The compound has been shown to possess anti-inflammatory activity through inhibition of the NLR Family pyrin domain-containing 3 (NLRP3) inflammasome and production of proinflammatory cytokines including interleukin (IL)-1β and IL-18. A more hydrophilic derivative of the compound also exhibited antitumor activity in the breast, colon, ovarian, and lung cancer. Some other synthetic derivatives of the compound have also been synthesized with antitumor, cytotoxic, antibacterial, and antifungal activities. Since both NLRP3 inflammasome and cytokine storm are associated with the pathogenesis of COVID-19 and its lethality, compounds like arglabin might have therapeutic potential to attenuate the inflammasome-induced acute respiratory distress syndrome and/or the cytokine storm associated with COVID-19.
引用
收藏
页码：8221 / 8225
页数：4
相关论文
共 118 条
  • [1] Sohrabi C(2020)World Health Organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19) Int J Surg 76 71-76
  • [2] Alsafi Z(2020)Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): an update Cureus 12 e7423-609
  • [3] O’Neill N(2020)Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series BMJ 368 m606-577
  • [4] Pal M(2014)The story of beta-sitosterol-a review Eur J Med Plants 4 590-964
  • [5] Berhanu G(2017)Bioactive sesquiterpene lactone from Boletín Latinoamericano y del Caribe de Plantas Medicinales y Aromáticas 16 570-661
  • [6] Desalegn C(2020) spp. derivatives for COVID-19 treatment: anecdotal use, political hype, treatment potential, challenges, and road map to randomized clinical trials Am J Trop Med Hyg 103 960-103
  • [7] Kandi V(2016)Natural products as sources of new drugs from 1981 to 2014 J Nat Prod 79 629-198
  • [8] Xu XW(2020)Pay attention to situation of SARS-CoV-2 and TCM advantages in treatment of novel coronavirus infection Chin Herb Med 12 97-98
  • [9] Wu XX(2020)Traditional Chinese medicine for COVID-19 treatment Pharmacol Res 155 104743-624
  • [10] Jiang XG(2020)Anti-malarial drug, artemisinin and its derivatives for the treatment of respiratory diseases Pharmacol Res 158 104901-211
12345678910